Latham & Watkins Advises Coherus BioSciences in US$300 Million Credit Financing With Pharmakon Advisors

Coherus BioSciences, Inc. (Coherus or the Company) (Nasdaq: CHRS) has announced that it has entered into a loan agreement with investment funds managed by Pharmakon Advisors, LP. The credit facility provides Coherus with up to US$300 million committed across four tranches, subject to the terms and conditions of the loan agreement.

Latham & Watkins LLP represents Coherus with a transactional team led by Bay Area finance partners Haim Zaltzman and Dan Van Fleet, with associates Trevor Church and Brian Ferrell. Advice was also provided on corporate matters by Bay Area partners Ben Potter and Phillip Stoup and Bay Area counsel Heather Deixler; on capital markets matters by Los Angeles/New York partner Greg Rodgers, with associate Ryan Gold; on regulatory matters by Bay Area counsel Betty Pang, with associate Chad Jennings; on intellectual property matters by Bay Area partner Jekkie Kim; and on tax matters by Los Angeles partner Eric Cho, with associate Sam Yang.